Article info
PDFViewpoint
No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?
- Correspondence to Dr Juergen Braun, Rheumazentrum Ruhrgebiet, Herne 44649, Germany; juergen.braun{at}elisabethgruppe.de
Citation
No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?
Publication history
- Received August 27, 2021
- Accepted October 7, 2021
- First published October 16, 2021.
Online issue publication
October 18, 2023
Article Versions
- Previous version (10 March 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.